News about Drug Discovery & Development

Dr. Jitendra Singh Announces Soft Launch of Antibiotic Nafithromycin

The antibiotic ‘Nafithromycin’ has been developed with the support of Biotechnology Industry Research Assistance Council (BIRAC), a unit of the Department of Biotechnology and has been brought to market under the trade name ‘Miqnaf’ by pharma company ‘Wolkardt’.

Drug Discovery & Development | 22/11/2024 | By Aishwarya |  973

Lupin Introduces Bumetanide Injection in US

Bumetanide Injection USP, is a generic equivalent of Bumex Injection, 0.25 mg/mL of Validus Pharmaceuticals, LLC., indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.

Drug Discovery & Development | 22/11/2024 | By Aishwarya |  440

Alloy Therapeutics Signs License Deal with Takeda to Develop Cell Therapy Platform

Under the agreement, Alloy gains co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications.

Drug Discovery & Development | 21/11/2024 | By Aishwarya |  361

Syndax Gets FDA Approval of Revuforj for Relapsed or Refractory Acute Leukemia

The safety evaluation of Revuforj was based on an FDA analysis of 135 patients with R/R acute leukemia with a KMT2A translocation who were treated with Revuforj.

Drug Discovery & Development | 16/11/2024 | By Aishwarya |  450

Endo and Paladin Pharma to Commercialize Wynzora Cream in Canada

Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis, in adults.

Drug Discovery & Development | 16/11/2024 | By Aishwarya |  533

Reverb, Royalmount Laboratories to Develop Advanced Bispecific Antibodies

Reverb’s novel Amplify•R™ platform combines bispecific antibody engineering with data-driven modelling of antibody-tissue interaction to amplify endogenous cytokines and redirect them to tissues of interest.

Drug Discovery & Development | 14/11/2024 | By Aishwarya |  428

TAE Life Sciences and Stella Pharma to Commercialize BPA for BNCT Cancer Therapy

The collaboration objectives include extensive international cooperation in the development and commercialization of BNCT and BPA across the USA and Europe with clinical trials anticipated to begin in 2026.

Drug Discovery & Development | 14/11/2024 | By Aishwarya |  723

Chime Biologics and Waterstone to Advance ADC Development and Manufacturing

Through this collaboration, Chime Biologics and Waterstone will offer a comprehensive solution to the ADC developers for IND-enabling and clinical studies.

Drug Discovery & Development | 13/11/2024 | By Aishwarya |  261

Lupin Gets Tentative Approval from FDA for Raltegravir Tablets

Raltegravir Tablets USP, 600 mg are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients and in pediatric patients weighing at least 40 kg.

Drug Discovery & Development | 11/11/2024 | By Aishwarya |  362

Huons Acquires Stake in PanGen to Expand Bio-Pharma Business

Huons will own PanGen shares through the acquisition of existing shareholders and a paid-in capital increase via third-party allocation.

Drug Discovery & Development | 08/11/2024 | By Aishwarya |  534